Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Validation study paves way for large-scale trial of personalized therapy
December 28th, 2004
The overall performance of the gene signature to be used in the first large-scale trial to study the role of such tumor signatures in breast cancer is encouraging and gives the green light to start the trial proper, Martine Piccart, head of the medical oncology department at the Institut Jules Bordet in Brussels, Belgium, told the San Antonio Breast Cancer conference on December 8, 2004. Piccart heads the TRANSBIG consortium, which intends to use the 70-gene prognostic signature developed by the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL) in MINDACT, a large, prospective, international, randomized clinical trial for lymph node-negative breast...
Source: Cancer Weekly (2004-12-28)
|
